Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/175775
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pasculli, Barbara | - |
dc.contributor.author | Barbano, Raffaela | - |
dc.contributor.author | Fontana, Andrea | - |
dc.contributor.author | Biagini, Tommaso | - |
dc.contributor.author | Viesti, Maria Pia Di | - |
dc.contributor.author | Rendina, Michelina | - |
dc.contributor.author | Valori, Vanna Maria | - |
dc.contributor.author | Morritti, Maria | - |
dc.contributor.author | Bravaccini, Sara | - |
dc.contributor.author | Ravaioli, Sara | - |
dc.contributor.author | Maiello, Evaristo | - |
dc.contributor.author | Graziano, Paolo | - |
dc.contributor.author | Murgo, Roberto | - |
dc.contributor.author | Copetti, Massimiliano | - |
dc.contributor.author | Mazza, Tommaso | - |
dc.contributor.author | Fazio, Vito Michele | - |
dc.contributor.author | Esteller, Manel | - |
dc.contributor.author | Parrella, Paola | - |
dc.date.accessioned | 2021-03-25T16:17:36Z | - |
dc.date.available | 2021-03-25T16:17:36Z | - |
dc.date.issued | 2020-08-12 | - |
dc.identifier.issn | 2234-943X | - |
dc.identifier.uri | http://hdl.handle.net/2445/175775 | - |
dc.description.abstract | miR-155-5p is a well-known oncogenic microRNA, showing frequent overexpression in human malignancies, including breast cancer. Here, we show that high miR-155-5p levels are associated with unfavorable prognostic factors in two independent breast cancer cohorts (CSS cohort, n = 283; and TCGA-BRCA dataset, n = 1,095). Consistently, miR-155-5p results as differentially expressed in the breast cancer subgroups identified by the surrogate molecular classification in the CSS cohort and the PAM50 classifier in TCGA-BRCA dataset, with the TNBC and HER2-amplified tumors carrying the highest levels. Since the analysis of TCGA-BC dataset also demonstrated a significant association between miR-155-5p levels and the presence of mutations in homologous recombination (HR) genes, we hypothesized that miR-155-5p might affect cell response to the PARP-1 inhibitor Olaparib. As expected, miR-155-5p ectopic overexpression followed by Olaparib administration resulted in a greater reduction of cell viability as compared to Olaparib administration alone, suggesting that miR-155-5p might induce a synthetic lethal effect in cancer cells when coupled with PARP-1-inhibition. Overall, our data point to a role of miR-155-5p in homologous recombination deficiency and suggest miR-155-5p might be useful in predicting response to PARP1 inhibitors in the clinical setting. | - |
dc.format.extent | 14 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Frontiers Media | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3389/fonc.2020.01415 | - |
dc.relation.ispartof | Frontiers In Oncology, 2020, vol. 10 | - |
dc.relation.uri | https://doi.org/10.3389/fonc.2020.01415 | - |
dc.rights | cc-by (c) Pasculli, Bárbara et al., 2020 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Ciències Fisiològiques) | - |
dc.subject.classification | Càncer de mama | - |
dc.subject.classification | Inhibidors enzimàtics | - |
dc.subject.classification | Oncogens | - |
dc.subject.other | Breast cancer | - |
dc.subject.other | Enzyme inhibitors | - |
dc.subject.other | Oncogenes | - |
dc.title | Hsa-miR155-5p up-regulation in Breast Cancer and its relevance for treatment with Poly [ADP-ribose] polymerase 1 (PARP-1) inhibitors | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 704181 | - |
dc.date.updated | 2021-03-25T16:17:36Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 32903519 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Fisiològiques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
704181.pdf | 1.46 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License